David Sinclair's Supplement Stack: The Complete 2026 Protocol

David Sinclair is a professor of genetics at Harvard Medical School, co-director of the Paul F. Glenn Center for Biology of Aging Research, and author of Lifespan: Why We Age – and Why We Don't Have To. He is arguably the most influential figure in longevity science and has been publicly transparent about the supplements and medications he takes.

This article documents his complete current protocol as of 2026, based on his podcast appearances, public statements, and interviews – including his June 2025 interview with Peter Diamandis and his March 2026 appearance on The Diary of a CEO with Steven Bartlett.

Critical disclaimer: Sinclair is a researcher, not a physician. He has consistently stated that he does not recommend his personal protocol to others. Several compounds in his stack are prescription medications with significant side effect profiles. This article is educational – documenting what one scientist takes and why, with honest assessment of the evidence for each compound.

TL;DR

• Core stack: NMN 1g, resveratrol 1g (with yogurt), berberine 1g (replaced metformin), fisetin 500mg
• Additional: spermidine, alpha-lipoic acid, vitamin D3+K2, omega-3, nattokinase, CoQ10, low-dose aspirin
• Prescription: rapamycin (~4x/year), statin 80mg
• Key 2025–2026 changes: berberine replaced metformin, rapamycin reduced to intermittent, TMG dropped
• Sinclair emphasizes supplements are ~20% of his strategy – lifestyle (fasting, exercise, sleep) is the other 80%

What Changed Since Lifespan (2019)

Sinclair's protocol has evolved significantly since he published Lifespan in 2019. The core NMN + resveratrol backbone remains, but several compounds have been added, modified, or dropped. Here are the major changes:

Safety Warning: Several compounds in Sinclair's stack are prescription medications (metformin/berberine, rapamycin, statins). Self-prescribing these without medical supervision carries serious risks including immunosuppression (rapamycin), lactic acidosis (metformin), and muscle damage (statins). This article documents Sinclair's protocol – it is not a recommendation to replicate it.

Watch: Sinclair's full Diary of a CEO interview — covering his aging reversal research, personal protocol, and the science behind his supplement stack:

The Complete 2026 Protocol

NMN – 1g (1,000mg) Daily

What it is: NMN (nicotinamide mononucleotide) is the direct precursor to NAD+ (nicotinamide adenine dinucleotide – a coenzyme required for 500+ cellular processes including DNA repair, energy production, and sirtuin enzyme activity).

Why Sinclair takes it: NAD+ levels decline approximately 50% between ages 40 and 60. NMN supplementation reliably restores them. The Yi et al. 2023 trial (n=80) found 600mg optimal for functional outcomes. Sinclair's 1g dose exceeds this, reflecting his personal interpretation of early mouse dose-conversion studies.

When he takes it: Morning, mixed with yogurt.

What the evidence shows: At least 18 human RCTs confirm NMN elevates NAD+ and improves physical performance, insulin sensitivity, and sleep quality at doses of 250–900mg. No trial has tested 1g specifically in a controlled setting, but the 900mg arm of Yi et al. 2023 showed no safety concerns. See NMN Dosage Guide: How Much Should You Take? for the full dose-response analysis.

Honest assessment: NMN at 1g is likely safe but not evidence-optimized. The clinical data supports 600mg as the functional sweet spot. Sinclair may benefit from his higher dose, but the marginal benefit over 600mg is unproven.

Resveratrol – 1g (1,000mg) Daily

What it is: Resveratrol is a polyphenol (a plant-derived compound with antioxidant and anti-inflammatory properties) found in grape skins, red wine, and Japanese knotweed. It activates SIRT1 (the most studied longevity sirtuin) through AMPK (AMP-activated protein kinase – a cellular energy sensor that triggers beneficial metabolic adaptations) signaling and direct enzyme binding.

Why Sinclair takes it: Resveratrol activates the sirtuin enzymes that NMN fuels. Sinclair describes resveratrol as "the accelerator pedal" for sirtuins, with NMN as the fuel. The combination elevated NAD+ 1.6–1.7x more than NMN alone in preclinical models. See NMN and Resveratrol Together: The Synergy for the complete mechanism.

When he takes it: Morning, with yogurt. The fat in yogurt is critical – resveratrol is lipophilic (dissolves in fat, not water) and has negligible oral bioavailability without a fat source. Sinclair has specifically noted that he learned this matters: without fat, most resveratrol passes through unabsorbed.

What the evidence shows: Resveratrol at doses of 150–1,000mg has shown benefits in human trials for cardiovascular markers, glucose metabolism, and inflammatory markers (Timmers et al., 2011, Cell Metabolism; Turner et al., 2015, Clinical Nutrition). The sirtuin activation mechanism is well-established (Hubbard et al., 2013, Science). See Resveratrol in 2026: What 20 Years of Science Has Actually Proven for the complete evidence review.

Honest assessment: Resveratrol's mechanisms are solid, but the human longevity evidence is still indirect – improved biomarkers, not lifespan extension. The 1g dose is higher than most trials tested. Micronized trans-resveratrol is significantly better absorbed than standard resveratrol.

Berberine – 1g Daily (Replaced Metformin)

What it is: Berberine is a plant alkaloid (a nitrogen-containing compound extracted from bark and roots, particularly the Berberis genus) that activates AMPK, the same master energy-sensing pathway targeted by metformin.

Why Sinclair switched from metformin: In his June 2025 interview with Peter Diamandis, Sinclair revealed that metformin was "hard on his stomach." This is common – metformin's most frequent side effect is GI distress (nausea, diarrhea, cramping). Berberine activates many of the same pathways with a different GI tolerance profile.

The AMPK connection: Both metformin and berberine activate AMPK, which:

• Increases insulin sensitivity
• Enhances fat oxidation
• Inhibits mTOR (mechanistic target of rapamycin – a master growth-regulating enzyme that promotes cell division; inhibiting it mimics caloric restriction signaling)
• Promotes autophagy (the cellular recycling process where damaged components are broken down and rebuilt)
• May mimic caloric restriction's longevity-associated signaling

What the evidence shows: A 2020 meta-analysis (Liang et al., Frontiers in Pharmacology) of 46 RCTs found berberine significantly reduced fasting glucose, HbA1c, triglycerides, and LDL cholesterol in humans. Its glucose-lowering effect is comparable to metformin in head-to-head trials (Yin et al., 2008, Metabolism). See Berberine: The Plant Compound With Metformin-Like Effects for the full analysis.

Honest assessment: Berberine has strong human data for metabolic health. Its longevity effects are inferred from AMPK activation and caloric-restriction mimicry, not from human lifespan studies. The switch from metformin makes practical sense given similar mechanisms and better tolerability.

Key Takeaway: Sinclair's core trio – NMN, resveratrol, and berberine – targets the two most validated longevity pathways: NAD+/sirtuin activation (NMN + resveratrol) and AMPK/mTOR nutrient sensing (berberine). These pathways overlap with caloric restriction signaling, which is the most consistently life-extending intervention across species.

Fisetin – 500mg Daily

What it is: Fisetin is a flavonoid (a class of plant pigments with antioxidant properties) found in strawberries, apples, persimmons, and onions. It has senolytic properties (the ability to selectively destroy senescent cells – "zombie cells" that accumulate with age, secrete inflammatory signals, and damage surrounding healthy tissue).

Why Sinclair takes it: The Yousefzadeh et al. 2018 study from Mayo Clinic screened 10 flavonoids and ranked fisetin as the most potent senolytic compound, showing significant reduction in senescent cell burden and extension of both healthspan and lifespan in aged mice. Sinclair takes 500mg daily as a maintenance dose for ongoing senescent cell clearance.

What the evidence shows: The mouse data is strong. The AFFIRM-LITE human trial is evaluating fisetin in older adults but results are not yet published as of March 2026. The NIA's Interventions Testing Program (ITP) found fisetin did not extend lifespan in mice when administered in their specific protocol – creating genuine scientific debate about the compound. See Fisetin: The Senolytic Compound That Clears Zombie Cells for the complete evidence.

Honest assessment: Fisetin has the strongest preclinical senolytic data among natural compounds, but the ITP result is a legitimate counterpoint. The AFFIRM-LITE trial will be pivotal. Daily dosing at 500mg is Sinclair's choice – other practitioners use intermittent "pulse" protocols (high-dose for 2–3 days monthly). The optimal protocol in humans remains undefined. For a comparison with the other major senolytic, see Fisetin vs Quercetin: Which Senolytic Should You Take?.

Spermidine – 1–2mg Daily

What it is: Spermidine is a polyamine (a class of organic compounds with multiple amine groups) found in wheat germ, soybeans, aged cheese, and mushrooms. It is a potent inducer of autophagy – the cellular recycling process that clears damaged proteins and organelles.

Why Sinclair takes it: Autophagy declines with age, contributing to the accumulation of dysfunctional mitochondria, misfolded proteins, and cellular debris. Spermidine induces autophagy by inhibiting the acetyltransferase EP300, which normally suppresses autophagy initiation. Epidemiological data from the Bruneck Study (Kiechl et al., 2018, American Journal of Clinical Nutrition, n=829) found that higher dietary spermidine intake was associated with reduced all-cause mortality over a 20-year follow-up. See Autophagy: Your Body's Cellular Recycling System and Spermidine: The Autophagy Activator From Your Kitchen.

Honest assessment: The epidemiological association is compelling, and the autophagy mechanism is well-established in cell and animal models. However, the Bruneck Study is observational – people who eat more spermidine-rich foods likely have healthier overall diets. Supplemental spermidine at 1–2mg has limited human intervention data.

Alpha-Lipoic Acid (ALA) – ~500mg Daily

What it is: ALA (alpha-lipoic acid) is a mitochondrial coenzyme and antioxidant (a molecule that neutralizes reactive oxygen species – unstable molecules that damage DNA, proteins, and lipids) that is both fat- and water-soluble, giving it activity in all cellular compartments.

Why Sinclair takes it: ALA participates in mitochondrial energy metabolism as a cofactor for pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase. It also regenerates other antioxidants including vitamin C and glutathione (the body's primary intracellular antioxidant).

What the evidence shows: Human trials show ALA improves insulin sensitivity, reduces inflammatory markers, and supports nerve function in diabetic neuropathy (Ziegler et al., 2006, Diabetes Care, n=181). Its role in longevity specifically is less established.

Honest assessment: ALA has solid metabolic and neuroprotective evidence. Its longevity-specific contribution to Sinclair's stack is less clear than NMN, resveratrol, or berberine.

Vitamin D3 + K2

What it is: Vitamin D3 (cholecalciferol) is a fat-soluble hormone precursor critical for calcium metabolism, immune function, and gene regulation. Vitamin K2 (menaquinone) directs calcium into bones rather than arteries.

Why Sinclair takes it: Vitamin D deficiency is epidemic (estimated 40% of US adults are deficient) and associated with increased all-cause mortality in multiple large cohort studies. K2 is paired to prevent arterial calcification.

What the evidence shows: The VITAL trial (Manson et al., 2019, NEJM, n=25,871) found vitamin D supplementation reduced cancer mortality by 25% in a secondary analysis, though the primary outcome (cancer incidence) was not significantly reduced. D3+K2 combination is supported by the Rotterdam Study showing K2 intake inversely associated with cardiovascular mortality.

Honest assessment: One of the most evidence-supported supplements in any longevity stack. D3 at 2,000–4,000 IU daily with K2 is recommended by multiple medical authorities regardless of longevity goals.

Omega-3 Fatty Acids (Fish Oil)

What it is: EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) – anti-inflammatory polyunsaturated fatty acids found in fatty fish and fish oil supplements.

Why Sinclair takes it: Omega-3s reduce systemic inflammation (a key driver of aging, often called "inflammaging" – see Inflammaging: How Chronic Inflammation Accelerates Aging), support cardiovascular health, and maintain neuronal membrane integrity.

What the evidence shows: The REDUCE-IT trial (Bhatt et al., 2019, NEJM, n=8,179) demonstrated a 25% reduction in cardiovascular events with high-dose EPA. Multiple meta-analyses confirm omega-3 supplementation reduces triglycerides, blood pressure, and inflammatory markers.

Honest assessment: Among the most evidence-supported supplements. The benefit is clearest for cardiovascular health and systemic inflammation reduction.

Nattokinase

What it is: Nattokinase is a fibrinolytic enzyme (a protein that dissolves fibrin, the structural component of blood clots) extracted from natto, a Japanese fermented soybean food.

Why Sinclair takes it: Nattokinase breaks down fibrin in the bloodstream, potentially reducing the risk of pathological blood clots (thrombosis). It may also modestly reduce blood pressure.

What the evidence shows: A 2022 meta-analysis (Chen et al., Nutrition Research) found nattokinase supplementation significantly reduced systolic and diastolic blood pressure. Its fibrinolytic activity is well-established in vitro and in small human studies.

Honest assessment: Promising but limited evidence base compared to other compounds in this stack. The fibrinolytic mechanism is real, but large-scale cardiovascular outcome trials are lacking.

Safety Warning: Nattokinase has significant anticoagulant properties. Do NOT combine with blood thinners (warfarin, aspirin, apixaban) without physician supervision. The risk of excessive bleeding is real and clinically significant.

CoQ10 (Ubiquinol)

What it is: CoQ10 (coenzyme Q10 – a fat-soluble compound essential for mitochondrial electron transport and cellular energy production) exists in two forms: ubiquinone (oxidized) and ubiquinol (reduced, active form). Sinclair takes the ubiquinol form. See CoQ10: The Mitochondrial Fuel Your Cells Need for the complete science.

Why Sinclair takes it: Statin medications deplete CoQ10 as a side effect of inhibiting the mevalonate pathway (the metabolic pathway that produces both cholesterol and CoQ10). Sinclair takes a statin – CoQ10 supplementation offsets this depletion.

Honest assessment: Essential for anyone on statin therapy. The evidence for CoQ10 supplementation in non-statin users is less compelling for longevity specifically.

Low-Dose Aspirin – 81mg Daily

What it is: Aspirin (acetylsalicylic acid) at low dose inhibits cyclooxygenase-1 (COX-1), reducing platelet aggregation and lowering cardiovascular event risk.

Why Sinclair takes it: Low-dose aspirin has decades of evidence for secondary cardiovascular prevention. Its role in primary prevention (for people without existing heart disease) has become more nuanced – the ASPREE trial (McNeil et al., 2018, NEJM, n=19,114) found that daily aspirin did not significantly reduce cardiovascular events in healthy older adults but did increase major bleeding.

Honest assessment: Sinclair likely takes this for overall cardiovascular risk management. For individuals without established cardiovascular disease, the risk-benefit calculus for low-dose aspirin has shifted. Discuss with your physician.

Rapamycin – ~4 Times Per Year (Previously Weekly)

What it is: Rapamycin (sirolimus) is an immunosuppressant drug that inhibits mTOR (mechanistic target of rapamycin). At low doses, it has emerged as perhaps the most promising pharmaceutical longevity candidate.

Why Sinclair takes it: In the NIA Interventions Testing Program, rapamycin extended mouse lifespan by 9–14% – the most consistent result of any compound tested. It works by inhibiting mTOR, shifting cellular signaling from growth mode to repair mode – mimicking caloric restriction. See mTOR and AMPK: The Aging Switches Inside Every Cell and Rapamycin: The Most Promising Anti-Aging Drug for the complete mechanism.

What changed: Sinclair previously took rapamycin more frequently (weekly). In his June 2025 interview, he mentioned that recent epigenetic aging studies found rapamycin didn't appear to improve epigenetic age measures, while caloric restriction, acarbose, and metformin fared better. He now takes rapamycin approximately 4 times per year.

Honest assessment: Rapamycin has the strongest animal lifespan-extension data of any pharmaceutical. The human longevity data is limited to the PEARL trial and ongoing studies. Rapamycin is an immunosuppressant – even at low doses, it carries real risks including mouth sores, impaired wound healing, and increased infection susceptibility. This is a prescription drug that requires medical supervision.

Statin – 80mg Daily

What it is: Statins are HMG-CoA reductase inhibitors that lower LDL cholesterol by blocking the mevalonate pathway in the liver.

Why Sinclair takes it: Likely prescribed for cardiovascular risk management based on his lipid profile. Statins are among the most evidence-supported medications in all of medicine for reducing cardiovascular mortality in appropriate patients.

Honest assessment: Statins are not longevity supplements – they are prescription medications with a robust evidence base for cardiovascular risk reduction. They also deplete CoQ10, which is why Sinclair supplements it.

Key Takeaway: Sinclair's most significant 2025-2026 change was switching from metformin to berberine and reducing rapamycin from weekly to ~4x/year. These adjustments reflect an evolving, data-responsive approach -- not a fixed protocol. If even Sinclair modifies his stack based on new evidence and personal biomarkers, any longevity protocol should be treated as iterative, not permanent.

Key Takeaway: Sinclair's stack targets four core longevity mechanisms: NAD+/sirtuin activation (NMN + resveratrol), AMPK/nutrient sensing (berberine), senescent cell clearance (fisetin), and autophagy induction (spermidine + rapamycin). Each compound has a specific mechanistic rationale, but the overall evidence ranges from strong (NMN, resveratrol, omega-3, vitamin D) to emerging (fisetin, spermidine, nattokinase).

Key Takeaway: The strongest-evidence compounds in Sinclair's stack -- NMN, resveratrol, vitamin D3+K2, and omega-3s -- are the ones with the broadest independent clinical support. The emerging compounds (fisetin, spermidine, nattokinase) have compelling mechanisms but thinner human data. If budget is limited, prioritize the evidence-heavy tier first.

What Sinclair Emphasizes Beyond Supplements

In virtually every interview, Sinclair makes the same point: supplements are roughly 20% of his longevity strategy. The other 80% is lifestyle:

1. Intermittent fasting: Sinclair skips breakfast, having only black coffee in the morning. He typically eats lunch and dinner within an approximately 8-hour window. He considers fasting "non-negotiable." See Intermittent Fasting and Longevity Supplements.
2. Exercise: Regular cardiovascular and resistance training. He emphasizes that exercise activates many of the same pathways his supplements target (AMPK, NAD+, sirtuins, autophagy). See Exercise and Longevity: What the Evidence Actually Shows.
3. Cold and heat exposure: Sinclair has mentioned using cold exposure to activate brown fat and metabolic stress responses.
4. Sleep: He prioritizes consistent sleep timing and duration, noting that NAD+ oscillation is circadian-dependent.
5. Biomarker tracking: Sinclair regularly measures biological age using epigenetic clocks and monitors blood biomarkers including NAD+ levels, inflammatory markers, and metabolic panels.

Key Takeaway: Sinclair consistently states that supplements account for roughly 20% of his longevity strategy, with lifestyle -- intermittent fasting, exercise, sleep, and cold/heat exposure -- comprising the other 80%. No supplement stack can compensate for poor sleep, a sedentary lifestyle, or a processed food diet.

The Sinclair Controversy: Deserved Skepticism and Valid Science

Any article about David Sinclair in 2026 must acknowledge the controversy surrounding him. In late 2024, a Wall Street Journal investigation raised questions about some of Sinclair's research claims and commercial ventures. He subsequently stepped down from a prominent aging academy position.

This context matters. But it does not invalidate the underlying science of the compounds he takes:

What the controversy affects:

• Sinclair's personal credibility as an unbiased science communicator
• The commercial ventures he has been involved with
• Specific claims about biological age reversal that exceeded the published evidence

What the controversy does not affect:

• The independently replicated NMN human trials (Yi et al. 2023 was not Sinclair's lab)
• The well-established NAD+/sirtuin biochemistry (confirmed by dozens of independent research groups)
• The AMPK/mTOR nutrient-sensing pathways (metformin/berberine)
• The independently validated senolytic research (Kirkland's Mayo Clinic work on fisetin and D+Q)

The compounds in Sinclair's stack are not "Sinclair's compounds." They are extensively studied molecules with independent evidence bases. Evaluating them should be based on the clinical data, not on any single researcher's reputation.

Bryan Johnson – who approaches longevity with perhaps the most rigorous self-quantification protocol in existence – takes many of the same compounds independently. The convergence of multiple sophisticated practitioners on overlapping protocols suggests the underlying mechanisms are sound, even if individual advocacy requires scrutiny.

Safety Note: This documents one individual's personal protocol, not medical advice. Several compounds in this stack (rapamycin, metformin, high-dose fisetin) are prescription drugs or carry significant interaction risks. Do not replicate this stack without physician oversight.

What to Take From Sinclair's Protocol (and What to Leave)

Sinclair's stack is informative but not prescriptive. Here is a framework for contextualizing it:

Strongest evidence (safe for most adults):

• Vitamin D3 + K2 – widely recommended, low risk, high deficiency prevalence
• Omega-3 fatty acids – strong cardiovascular evidence, anti-inflammatory
• NMN 600mg – 18+ human RCTs, well-tolerated (600mg is evidence-optimized, not 1g)
• Resveratrol with fat – solid sirtuin activation mechanism, human metabolic benefits

Moderate evidence (reasonable with monitoring):

• Berberine – strong metabolic data but can lower blood sugar; monitor glucose
• TMG – mechanistically sound for NMN pairing; Sinclair may have dropped it but the biochemistry supporting it hasn't changed
• Spermidine – compelling epidemiological and autophagy data; limited interventional evidence
• CoQ10 – essential if on statins; beneficial for mitochondrial support generally

Emerging evidence (proceed with caution):

• Fisetin – strong preclinical data but conflicting ITP results; AFFIRM-LITE pending
• Nattokinase – real fibrinolytic activity but limited large-scale human data
• Alpha-lipoic acid – metabolic benefits established; longevity-specific role less clear

For an independent evidence ranking of every compound in Sinclair's protocol, see the Compound Index.

Prescription only (requires physician):

• Rapamycin – strongest animal lifespan data; immunosuppressant with real risks
• Statins – cardiovascular standard of care; prescribed based on individual lipid profile
• Low-dose aspirin – risk-benefit ratio shifted by ASPREE trial; discuss with physician

Frequently Asked Questions

Related Reading

• What Is NMN? The Complete Guide to Nicotinamide Mononucleotide
• Resveratrol in 2026: What 20 Years of Science Has Actually Proven
• TMG: The Methylation Partner Your NMN Needs
• NMN and Resveratrol Together: The Synergy
• Rapamycin: The Most Promising Anti-Aging Drug
• Taurine and Longevity: What the Science Shows
• Fisetin: The Senolytic Compound That Clears Zombie Cells
• Spermidine: The Autophagy Activator From Your Kitchen

References:

• Yi L, et al. NMN supplementation in healthy middle-aged adults. GeroScience. 2023;45(1):29–43. n=80.
• Hubbard BP, et al. Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science. 2013;339(6124):1216–1219.
• Liang Y, et al. Effects of berberine on blood glucose in patients with type 2 diabetes: a systematic review and meta-analysis. Front Pharmacol. 2020.
• Yin J, et al. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008;57(5):712–717.
• Yousefzadeh MJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18–28.
• Kiechl S, et al. Higher spermidine intake is linked to lower mortality. Am J Clin Nutr. 2018;108(2):371–380. n=829.
• Manson JE, et al. Vitamin D supplements and prevention of cancer and cardiovascular disease. NEJM. 2019;380(1):33–44. n=25,871.
• Bhatt DL, et al. Cardiovascular risk reduction with icosapent ethyl. NEJM. 2019;380(1):11–22. n=8,179.
• McNeil JJ, et al. Effect of aspirin on disability-free survival in the healthy elderly. NEJM. 2018;379(16):1499–1508. n=19,114.
• Timmers S, et al. Calorie restriction-like effects of resveratrol on energy metabolism. Cell Metabolism. 2011;14(5):612–622.
• Ziegler D, et al. Treatment of diabetic neuropathy with alpha-lipoic acid. Diabetes Care. 2006;29(11):2365–2370. n=181.

These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.